Advances in the design and synthesis of prazosin derivatives over the last ten years

Bibliography

• Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 2011;51:518-28
   PubMed Web of Science ®Google Scholar
• Cotecchia S. The alpha1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res 2010;15:410-19
   Web of Science ®Google Scholar
• Hwa J, Graham RM, Perez DM. Identification of critical determinants of alpha1-adrenergic receptor subtype selective agonist binding. J Biol Chem 1995;270:23189-95
   PubMed Web of Science ®Google Scholar
• Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res 2001;44:195-208
   PubMed Web of Science ®Google Scholar
• Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. Fos/jun expression is associated with sarcomere assembly; egr-1 induction is primarily an alpha1-mediated response. J Biol Chem 1990;265:13809-17
   PubMed Web of Science ®Google Scholar
• Knowlton KU, Michel MC, Itani M, The alpha1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993;268:15374-80
   PubMed Web of Science ®Google Scholar
• Michelotti GA, Price DT, Schwinn DA. alpha1-adrenergic receptor regulation: Basic science and clinical implications. Pharmacol Ther 2000;88:281-309
   PubMed Web of Science ®Google Scholar
• Ramirez MT, Sah VP, Zhao XL., The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem 1997;272:14057-61
   PubMed Web of Science ®Google Scholar
• Boluyt MO, Zheng JS, Younes A, Rapamycin inhibits alpha1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 s6 kinase. Circ Res 1997;81:176-86
   PubMed Web of Science ®Google Scholar
• Kimura M, Ogihara M. Stimulation by transforming growth factor-alpha of DNA synthesis and proliferation of adult rat hepatocytes in primary cultures: Modulation by alpha- and beta-adrenoceptor agonists. J Pharmacol Exp Ther 1999;291:171-80
   PubMed Web of Science ®Google Scholar
• Nguyen VA, Gao B. Cross-talk between alpha1B-adrenergic receptor (alpha1BAR) and interleukin-6 (IL-6) signaling pathways. Activation of alpha1BAR inhibits il-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism. J Biol Chem 1999;274:35492-8
   PubMed Web of Science ®Google Scholar
• Lin RZ, Chen J, Hu ZW, Hoffman BB. Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha1 adrenergic receptors. J Biol Chem 1998;273:30033-8
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193-206
   PubMedGoogle Scholar
• Sydorenko V, Shuba Y, Thebault S, Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells. J Physiol 2003;548:823-36
   PubMed Web of Science ®Google Scholar
• Thebault S, Flourakis M, Vanoverberghe K, Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006;66:2038-47
   PubMed Web of Science ®Google Scholar
• Shi T, Gaivin RJ, McCune DF, Dominance of the alpha1B-adrenergic receptor and its subcellular localization in human and tramp prostate cancer cell lines. J Recept Signal Transduct Res 2007;27-27-45
   PubMed Web of Science ®Google Scholar
• Park SY, Kang JH, Jeong KJ, Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 2011;128:2306-16
   PubMed Web of Science ®Google Scholar
• Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161:635-40
   PubMed Web of Science ®Google Scholar
• Kaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008;102(Suppl 2):3-7
   PubMed Web of Science ®Google Scholar
• Antonello A, Hrelia P, Leonardi A, Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. J Med Chem 2005;48:28-31
   PubMed Web of Science ®Google Scholar
• Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 1995;168:7-12
   PubMedGoogle Scholar
• Cohen BM. Prazosin hydrochloride (cp-12,299-1), an oral anti-hypertensive agent: preliminary clinical observations in ambulatory patients. J Clin Pharmacol J New Drugs 1970;10:408-17
   PubMedGoogle Scholar
• Brogden RN, Heel RC, Speight TM, Avery GS. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 1977;14:163-97
   PubMed Web of Science ®Google Scholar
• Stokes GS, Marwood JF. Review of the use of alpha-adrenoceptor antagonists in hypertension. Methods Find Exp Clin Pharmacol 1984;6:197-204
   PubMed Web of Science ®Google Scholar
• Taylor SH. Clinical pharmacotherapeutics of doxazosin. Am J Med 1989;87:2S-11S
   Web of Science ®Google Scholar
• Pool JL, Taylor AA, Nelson EB. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am J Med 1989;87:57S-61S
   PubMed Web of Science ®Google Scholar
• Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49:295-320
   PubMed Web of Science ®Google Scholar
• Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993;3:258-77
   PubMed Web of Science ®Google Scholar
• Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410-29
   PubMed Web of Science ®Google Scholar
• McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002;62:633-53
   PubMed Web of Science ®Google Scholar
• Nickel JC. Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int 2008;101(Suppl 3):11-16
   PubMed Web of Science ®Google Scholar
• Kyprianou N, Litvak JP, Borkowski A, Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-15
   PubMedGoogle Scholar
• Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-5
   PubMed Web of Science ®Google Scholar
• Yang G, Timme TL, Park SH, Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 1997;33:157-63
   PubMed Web of Science ®Google Scholar
• Anglin IE, Glassman DT, Kyprianou N. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: Mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002;5:88-95
   PubMed Web of Science ®Google Scholar
• Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-75
   PubMed Web of Science ®Google Scholar
• Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 2004;59:91-100
   PubMed Web of Science ®Google Scholar
• Xu K, Wang X, Ling PM, The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and rb independent pathway. Oncol Rep 2003;10:1555-60
   PubMed Web of Science ®Google Scholar
• Pan SL, Guh JH, Huang YW, Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 2003;169:724-9
   PubMed Web of Science ®Google Scholar
• Keledjian K, Borkowski A, Kim G, Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 2001;48:71-8
   PubMed Web of Science ®Google Scholar
• Fernando MA, Heaney AP. alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 2005;19:3085-96
   PubMed Web of Science ®Google Scholar
• Hui H, Fernando MA, Heaney AP. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer 2008;44:160-6
   PubMed Web of Science ®Google Scholar
• Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 1998;51:861-72
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61
   PubMed Web of Science ®Google Scholar
• Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001;58:508-16
   PubMed Web of Science ®Google Scholar
• Rosini M, Bolognesi ML, Giardina D, Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 2007;7:147-62
   PubMed Web of Science ®Google Scholar
• Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24
   PubMed Web of Science ®Google Scholar
• Rossi M, Roumeguere T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther 2010;4:291-7
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Ito H, Aoki Y, Selective alpha1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol 2010;28:609-14
   PubMed Web of Science ®Google Scholar
• Chapple CR, Montorsi F, Tammela TL, Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in europe. Eur Urol 2011;59:342-52
   PubMed Web of Science ®Google Scholar
• Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: Pharmacology and cardiovascular tolerability. Pharmacotherapy 2010;30:1303-12
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507
   PubMed Web of Science ®Google Scholar
• Garofalo A, Goossens L, Lemoine A, Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. J Enzyme Inhib Med Chem 2010;25:158-71
   PubMed Web of Science ®Google Scholar
• Garofalo A, Goossens L, Baldeyrou B, Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives. J Med Chem 2010;53:8089-103
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400
   PubMed Web of Science ®Google Scholar
• Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121:230-8
   PubMed Web of Science ®Google Scholar
• Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 2009;5:421-32
   PubMed Web of Science ®Google Scholar
• Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011;29:325-37
   PubMed Web of Science ®Google Scholar
• Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-60
   PubMed Web of Science ®Google Scholar
• Ansari J, Glaholm J, McMenemin R, Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem 2010;10:225-35
   PubMed Web of Science ®Google Scholar
• Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 2010;15:13-26
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009;2:161-8
   PubMedGoogle Scholar
• Gerstner ER, Duda DG, di Tomaso E, VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229-36
   PubMed Web of Science ®Google Scholar
• Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008;3:1173-84
   PubMed Web of Science ®Google Scholar
• Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009;18:1549-57
   PubMed Web of Science ®Google Scholar
• Marvania B, Lee PC, Chaniyara R, Design, synthesis and antitumor evaluation of phenyl n-mustard-quinazoline conjugates. Bioorg Med Chem 2011;19:1987-98
   PubMed Web of Science ®Google Scholar
• Kapuriya N, Kakadiya R, Dong H, Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. Bioorg Med Chem 2011;19:471-85
   PubMed Web of Science ®Google Scholar
• Chaniyara R, Kapuriya N, Dong H, Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2-b]isoquinoline derivatives, synthesis and biological activity. Bioorg Med Chem 2011;19:275-86
   PubMed Web of Science ®Google Scholar
• Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and IkappaBalpha induction. Br J Cancer 2003;88:1615-21
   PubMed Web of Science ®Google Scholar
• Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006;66:464-72
   PubMed Web of Science ®Google Scholar
• Shaw YJ, Yang YT, Garrison JB, Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 2004;47:4453-62
   PubMed Web of Science ®Google Scholar
• Garrison JB, Shaw YJ, Chen CS, Kyprianou N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 2007;67:11344-52
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Schwarze S, Kyprianou N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol 2011;59:734-44
   PubMed Web of Science ®Google Scholar
• Sirisoma N, Kasibhatla S, Pervin A, Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity. J Med Chem 2008;51:4771-9
   PubMed Web of Science ®Google Scholar
• Bauer J, Morley J, Spanton S, Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride. J Pharm Sci 2006;95:917-28
   PubMed Web of Science ®Google Scholar
• Rosini M, Antonello A, Cavalli A, Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. J Med Chem 2003;46:4895-903
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Marucci G, Angeli P, Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. J Med Chem 2001;44:362-71
   PubMed Web of Science ®Google Scholar
• Manetti F, Corelli F, Strappaghetti G, Botta M. Arylpiperazines with affinity toward alpha1-adrenergic receptors. Curr Med Chem 2002;9:1303-21
   PubMed Web of Science ®Google Scholar
• Betti L, Floridi M, Giannaccini G, Design, synthesis, and alpha1-adrenoceptor binding properties of new arylpiperazine derivatives bearing a flavone nucleus as the terminal heterocyclic molecular portion. Bioorg Med Chem 2004;12:1527-35
   PubMed Web of Science ®Google Scholar
• Minarini A, Budriesi R, Chiarini A, Search for alpha1-adrenoceptor subtypes selective antagonists: design, synthesis and biological activity of cystazosin, an alpha1D-adrenoceptor antagonist. Bioorg Med Chem Lett 1998;8:1353-8
   PubMed Web of Science ®Google Scholar
• Giardina D, Gulini U, Massi M, Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alpha-blocking activity. J Med Chem 1993;36:690-8
   PubMed Web of Science ®Google Scholar
• Giardina D, Crucianelli M, Melchiorre C, Receptor binding profile of cyclazosin, a new alpha1B-adrenoceptor antagonist. Eur J Pharmacol 1995;287:13-16
   PubMed Web of Science ®Google Scholar
• Sagratini G, Angeli P, Buccioni M, Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin. Bioorg Med Chem 2007;15:2334-45
   PubMed Web of Science ®Google Scholar
• Giardina D, Martarelli D, Sagratini G, Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity. J Med Chem 2009;52:4951-4
   PubMed Web of Science ®Google Scholar
• el-Sabbagh OI, Shabaan MA, Kadry HH, Al-Din ES. New octahydroquinazoline derivatives: Synthesis and hypotensive activity. Eur J Med Chem 2010;45:5390-6
   PubMed Web of Science ®Google Scholar
• Bremner JB, Griffith R, Coban B. Ligand design for alpha(1) adrenoceptors. Curr Med Chem 2001;8:607-20
   PubMed Web of Science ®Google Scholar
• MacDougall IJ, Griffith R. Selective pharmacophore design for alpha1-adrenoceptor subtypes. J Mol Graph Model 2006;25:146-57
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev 2011; published online 3 March 2011; doi: 10.1002/med.20239
   PubMed Web of Science ®Google Scholar
• Dey S, Ramachandra M, Pastan I, Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997;94:10594-9
   PubMed Web of Science ®Google Scholar
• Seidman CE, Hess HJ, Homcy CJ, Graham RM. Synthesis and characterization of a radioiodinated photoaffinity probe for the alpha 1-adrenergic receptor. Hypertension 1984;6-I 7-11
   Web of Science ®Google Scholar
• Andrus MB, Mettath SN, Song C. A modified synthesis of iodoazidoaryl prazosin. J Org Chem 2002;67:8284-6
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng XX, Kim IW, Erlotinib (tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-20
   PubMed Web of Science ®Google Scholar
• Dohse M, Scharenberg C, Shukla S, Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38:1371-80
   PubMed Web of Science ®Google Scholar
• El-Azab AS, Al-Omar MA, Abdel-Aziz AA, Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem 2010;45:4188-98
   PubMed Web of Science ®Google Scholar
• Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005;94:374-88
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 2010;31:205-14
   PubMed Web of Science ®Google Scholar
• Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003;169:1520-5
   PubMed Web of Science ®Google Scholar